354 related articles for article (PubMed ID: 27275478)
41. Pancreatic cancer symptom trajectories from Danish registry data and free text in electronic health records.
Hjaltelin JX; Novitski SI; Jørgensen IF; Siggaard T; Vulpius SA; Westergaard D; Johansen JS; Chen IM; Juhl Jensen L; Brunak S
Elife; 2023 Nov; 12():. PubMed ID: 37988407
[TBL] [Abstract][Full Text] [Related]
42. Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles.
Lakkakula BVKS; Farran B; Lakkakula S; Peela S; Yarla NS; Bramhachari PV; Kamal MA; Saddala MS; Nagaraju GP
Semin Cancer Biol; 2019 Jun; 56():149-167. PubMed ID: 30314681
[TBL] [Abstract][Full Text] [Related]
43. Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.
J Vis Exp; 2023 May; (195):. PubMed ID: 37235796
[TBL] [Abstract][Full Text] [Related]
44. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
Fitzgerald TL; Lertpiriyapong K; Cocco L; Martelli AM; Libra M; Candido S; Montalto G; Cervello M; Steelman L; Abrams SL; McCubrey JA
Adv Biol Regul; 2015 Sep; 59():65-81. PubMed ID: 26257206
[TBL] [Abstract][Full Text] [Related]
45. Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside.
Furukawa T
J Gastroenterol; 2008; 43(12):905-11. PubMed ID: 19107333
[TBL] [Abstract][Full Text] [Related]
46. A novel triptolide analog downregulates NF-κB and induces mitochondrial apoptosis pathways in human pancreatic cancer.
Tian Q; Zhang P; Wang Y; Si Y; Yin D; Weber CR; Fishel ML; Pollok KE; Qiu B; Xiao F; Chong AS
Elife; 2023 Oct; 12():. PubMed ID: 37877568
[TBL] [Abstract][Full Text] [Related]
47. Lipid metabolism in pancreatic cancer: emerging roles and potential targets.
Yin X; Xu R; Song J; Ruze R; Chen Y; Wang C; Xu Q
Cancer Commun (Lond); 2022 Dec; 42(12):1234-1256. PubMed ID: 36107801
[TBL] [Abstract][Full Text] [Related]
48. Evolution of systemic therapy for advanced pancreatic cancer.
Renouf D; Moore M
Expert Rev Anticancer Ther; 2010 Apr; 10(4):529-40. PubMed ID: 20397918
[TBL] [Abstract][Full Text] [Related]
49. Systemic treatment of pancreatic cancer.
Van Cutsem E; Aerts R; Haustermans K; Topal B; Van Steenbergen W; Verslype C
Eur J Gastroenterol Hepatol; 2004 Mar; 16(3):265-74. PubMed ID: 15195889
[TBL] [Abstract][Full Text] [Related]
50. Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis.
Mihaljevic AL; Michalski CW; Friess H; Kleeff J
Langenbecks Arch Surg; 2010 Apr; 395(4):295-308. PubMed ID: 20237938
[TBL] [Abstract][Full Text] [Related]
51. The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies.
Garcia-Sampedro A; Gaggia G; Ney A; Mahamed I; Acedo P
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33546207
[TBL] [Abstract][Full Text] [Related]
52. Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research.
Schütte U; Bisht S; Brossart P; Feldmann G
Expert Opin Drug Discov; 2011 Jan; 6(1):33-48. PubMed ID: 22646825
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer.
Yu M; Grady WM
Therap Adv Gastroenterol; 2012 Sep; 5(5):319-37. PubMed ID: 22973417
[TBL] [Abstract][Full Text] [Related]
54. Contemporary Management of Localized Resectable Pancreatic Cancer.
Kommalapati A; Tella SH; Goyal G; Ma WW; Mahipal A
Cancers (Basel); 2018 Jan; 10(1):. PubMed ID: 29361690
[TBL] [Abstract][Full Text] [Related]
55. Integrin β1 in Pancreatic Cancer: Expressions, Functions, and Clinical Implications.
Li J; Peng L; Chen Q; Ye Z; Zhao T; Hou S; Gu J; Hang Q
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884437
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
Adamopoulos C; Cave DD; Papavassiliou AG
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
[TBL] [Abstract][Full Text] [Related]
57. [Pharmacotherapy for pancreatic cancer: Difficulties and prospects].
Wang ZH; Zhou J; Shen L
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):712-716. PubMed ID: 28926903
[TBL] [Abstract][Full Text] [Related]
58. Molecular and genetic bases of pancreatic cancer.
Vaccaro V; Gelibter A; Bria E; Iapicca P; Cappello P; Di Modugno F; Pino MS; Nuzzo C; Cognetti F; Novelli F; Nistico P; Milella M
Curr Drug Targets; 2012 Jun; 13(6):731-43. PubMed ID: 22458519
[TBL] [Abstract][Full Text] [Related]
59. Update on current pancreatic treatments: from molecular pathways to treatment.
Sapalidis K; Kosmidis C; Funtanidou V; Katsaounis A; Barmpas A; Koimtzis G; Mantalobas S; Alexandrou V; Aidoni Z; Koulouris C; Pavlidis E; Giannakidis D; Surlin V; Pantea S; Strambu V; Constantina RO; Amaniti A; Zarogoulidis P; Mogoantă S; Kesisoglou I; Sardeli C
J Cancer; 2019; 10(21):5162-5172. PubMed ID: 31602269
[TBL] [Abstract][Full Text] [Related]
60. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
